FEC Followed by Docetaxel Improves Breast Ca Outcomes
February 01, 2005
SAN ANTONIO-Sequential therapy with three cycles of fluorouracil, epirubicin (Ellence) 100 mg/m2, and cyclophosphamide (FEC-100) followed by three cycles of docetaxel (Taxotere) improved outcomes over six cycles of FEC alone, in node-positive breast cancer patients over the age of 50. Professor Henri Roche, Institut Claudius Regaud, Tou-louse, France, reported the results of the multicenter study from France and Belgium at the 27th Annual San Antonio Breast Cancer Symposium (abstract 27). While the study also included younger women, the significant improvements in disease-free and overall survival were limited to women aged 50 and older.